Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» RBX2660
RBX2660
Go or no go? Bristol’s Tyk2 test
EP Vantage
Wed, 08/31/22 - 10:15 am
FDA
Bristol Myers Squibb
deucravacitinib
Amylyx Pharmaceuticals
ALS
AMX0035
Ferring Pharmaceuticals
microbiome
RBX2660
Revance Therapeutics
Bluebird Bio
Spectrum Pharmaceuticals
JNJ
Oncopeptides
FDA's vaccine adcomm to review first fecal transplant to treat C. difficile infections
Endpoints
Mon, 08/8/22 - 11:39 pm
FDA
Ferring Pharmaceuticals
Rebiotix
RBX2660
C. difficile
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Pharmaforum
Thu, 05/7/20 - 10:41 am
Ferring Pharmaceuticals
clinical trials
microbiome
C. difficile
RBX2660
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
CP Wire
Tue, 10/2/18 - 09:54 am
Rebiotix
RBX2660
C. difficile
microbiome
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
Mon, 10/1/18 - 11:29 pm
Rebiotix
RBX2660
C. difficile
microbiome